

27<sup>th</sup> July, 2016

To,  
The Secretary,  
The Bombay Stock Exchange,  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

**SUBJECT: BOARD MEETING OUTCOME**

**BSE CODE: 506197**

Dear Sir,

We like to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, 27<sup>th</sup> July, 2016 at the registered office of the company at 3.30 p.m. The Board has considered and approved the following:

- 1) Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Unaudited Standalone and Consolidated results for the quarter ended 30<sup>th</sup> June, 2016.
- 2) Limited Review Report for the quarter ended 30<sup>th</sup> June, 2016.
- 3) Pursuant to Section 188 of Companies Act, 2013, the Board considered the proposal of taking 9325 sq. ft. area at Hyde Park, Andheri (East) from the Promoters (Related Party Transaction) for the purpose of setting up the Research & Development unit/office.

Kindly acknowledged and take on record the same.

Thanking You,

For **BLISS GVS PHARMA LIMITED**

  
**VIPUL B. THAKKAR**

**CHIEF FINANCIAL OFFICER**



**Regd. Office :** 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : [info@blissgvs.com](mailto:info@blissgvs.com) • Website : [www.blissgvs.com](http://www.blissgvs.com) • CIN - L24230MH1984PLC034771

**Factory :** Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.  
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : [factory@blissgvs.com](mailto:factory@blissgvs.com)

**BLISS GVS PHARMA LIMITED**  
 Regd Office.102, Hyde Park, Sakivihar Road,  
 Andheri (East), Mumbai - 400 072  
**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS**  
**FOR THE QUARTER AND YEAR ENDED 30.06.2016**

SR. NO.	PARTICULARS	STANDALONE			
		QUARTER ENDED			YEAR ENDED
		30.06.2016 (UNAUDITED)	31.03.2016 (UNAUDITED)	30.06.2015 (UNAUDITED)	31.03.2016 (AUDITED)
1	<b>INCOME FROM OPERATIONS</b>				
	(a) SALES ( NET OF EXCISE DUTY)	6373.23	6092.27	7982.83	31969.24
	(b) OTHER OPERATING INCOME	215.85	468.00	42.05	669.11
	<b>TOTAL INCOME FROM OPERATIONS( NET)</b>	<b>6589.08</b>	<b>6560.27</b>	<b>8024.88</b>	<b>32638.35</b>
2	<b>EXPENSES</b>				
	a) COST OF MATERIALS CONSUMED	2998.84	3157.33	3517.88	13,647.00
	b) PURCHASE OF STOCK I N TRADE	-	-	36.37	36.37
	c) CHANGES IN INVENTORIES OF FINISHED GOODS ,WORK IN PROGRESS, STOCK IN TRADE	-160.88	124.02	15.90	-132.09
	d) EMPLOYEE BENEFITS EXPENSE	634.78	562.60	482.58	2188.89
	e) DEPRECIATION / AMORTISATION EXPENSES	144.30	143.92	135.22	585.24
	f) OTHER EXPENSES	1390.35	1150.83	1543.40	7288.36
	<b>TOTAL EXPENSES</b>	<b>5007.38</b>	<b>5138.70</b>	<b>5731.34</b>	<b>23613.77</b>
3	<b>PROFIT FROM OPERATIONS BEFORE OTHER INCOME &amp; FINANCE COSTS &amp; EXCEPTIONAL ITEMS ( 1-2)</b>	<b>1581.70</b>	<b>1421.57</b>	<b>2293.55</b>	<b>9024.58</b>
4	OTHER INCOME	741.85	267.34	630.78	2307.57
5	<b>PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS ( 3+4)</b>	<b>2323.54</b>	<b>1688.91</b>	<b>2924.32</b>	<b>11332.15</b>
6	FINANCE COSTS	290.08	305.13	291.18	1310.98
7	<b>PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)</b>	<b>2033.46</b>	<b>1383.78</b>	<b>2633.14</b>	<b>10021.17</b>
8	EXCEPTIONAL ITEMS	-	-	-	-
9	<b>PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX ( 7 - 8)</b>	<b>2033.46</b>	<b>1383.78</b>	<b>2633.14</b>	<b>10021.17</b>
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	650.71	915.71	1092.90	3459.70
11	<b>NET PROFIT AFTER TAX FOR THE PERIOD ( 9 - 10)</b>	<b>1382.75</b>	<b>468.07</b>	<b>1540.25</b>	<b>6561.47</b>
12	MINORITY INTEREST	-	-	-	-
13	<b>NET PROFIT AFTER TAX &amp; MINORITY INTEREST (11-12)</b>	<b>1382.75</b>	<b>468.07</b>	<b>1540.25</b>	<b>6561.47</b>
14	PAID - UP EQUITY SHARE CAPITAL	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET )				42175.96
16	<b>BASIC AND DILUTED EPS (NOT ANNUALISED) OF FACE VALUE OF RS. 1/- EACH</b>	<b>1.34</b>	<b>0.45</b>	<b>1.49</b>	<b>6.36</b>

**NOTES:-**

1.THE ABOVE UNAUDITED FINANCIAL RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON JULY 27, 2016

2.THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2016 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR AND THE YEAR TO DATE PUBLISHED RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2015.

3.THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.  
 GEOGRAPHICAL SEGMENT DISCLOSURE:-

- I) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 30, 2016 - RS. 498.89 LACS AND RS. 5874.34 LACS RESPECTIVELY  
 II) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED MARCH 31, 2016- RS. 375.84 LACS AND RS. 5716.43 LACS RESPECTIVELY  
 III) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 30, 2015- RS. 674.43 LACS AND RS. 7308.40 LACS RESPECTIVELY  
 IV) REVENUES WITHIN AND OUTSIDE INDIA FOR THE YEAR ENDED MARCH 31, 2016- RS. 2045.73 LACS AND RS. 29923.51 LACS RESPECTIVELY

4. FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI  
 DATE : 27th July 2016

FOR BLISS GVS PHARMA LTD  
 SD/-  
 S.N. KAMATH  
 MANAGING DIRECTOR

**BLISS GVS PHARMA LIMITED**  
 Regd Office.102, Hyde Park, Sakivihar Road,  
 Andheri (East), Mumbai - 400 072  
**STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS**  
**FOR THE QUARTER ENDED 30.06.2016**

(Rs. In Lacs)

**PART - I**

SR. NO.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2016 (UNAUDITED)	31.03.2016 (UNAUDITED)	30.06.2015 (UNAUDITED)	31.03.2016 (AUDITED)
1	<b>INCOME FROM OPERATIONS</b>				
	(a) SALES ( NET OF EXCISE DUTY)	13770.93	14041.07	9347.73	53671.30
	(b) OTHER OPERATING INCOME	243.41	771.53	140.43	1018.11
	<b>TOTAL INCOME FROM OPERATIONS( NET)</b>	<b>14014.34</b>	<b>14812.60</b>	<b>9488.16</b>	<b>54689.41</b>
2	<b>EXPENSES</b>				
	a) COST OF MATERIAL CONSUMED	6586.63	7457.36	3150.67	25,589.07
	b) PURCHASE OF STOCK IN TRADE	90.96	897.00	131.28	508.76
	c) CHANGES IN INVENTORIES OF FINISHED GOODS ,WORK IN PROGRESS, STOCK IN TRADE	(105.41)	(157.54)	68.18	(421.30)
	d) EMPLOYEE BENEFITS EXPENSE	1081.01	886.79	754.73	3373.65
	e) DEPRECIATION / AMORTISATION EXPENSES	360.27	345.81	304.17	1326.00
	f) OTHER EXPENSES	2424.50	2360.48	1889.50	10108.90
	<b>TOTAL EXPENSES</b>	<b>10437.96</b>	<b>11789.90</b>	<b>6298.53</b>	<b>40485.08</b>
3	<b>PROFIT FROM OPERATIONS BEFORE OTHER INCOME &amp; FINANCE COSTS &amp; EXCEPTIONAL ITEMS ( 1-2)</b>	<b>3576.38</b>	<b>3022.70</b>	<b>3189.63</b>	<b>14204.33</b>
4	OTHER INCOME	871.64	394.09	647.41	2435.00
5	<b>PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS ( 3+4)</b>	<b>4448.02</b>	<b>3416.79</b>	<b>3837.04</b>	<b>16639.33</b>
6	FINANCE COSTS	405.20	612.59	510.32	1819.86
7	<b>PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)</b>	<b>4042.82</b>	<b>2804.20</b>	<b>3326.72</b>	<b>14819.47</b>
8	EXCEPTIONAL ITEMS				
9	<b>PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX ( 7 - 8)</b>	<b>4042.82</b>	<b>2804.20</b>	<b>3326.72</b>	<b>14819.47</b>
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	1298.66	1472.92	1329.91	4804.91
11	<b>NET PROFIT AFTER TAX FOR THE PERIOD (9 - 10)</b>	<b>2744.16</b>	<b>1331.28</b>	<b>1996.81</b>	<b>10014.56</b>
12	MINORITY INTEREST	678.67	527.37	42.55	1766.30
13	<b>NET PROFIT AFTER TAX &amp; MINORITY INTEREST (11-12)</b>	<b>2065.49</b>	<b>803.91</b>	<b>1954.26</b>	<b>8248.26</b>
14	PAID - UP EQUITY SHARE CAPITAL	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET )				40230.77
16	<b>BASIC AND DILUTED EPS (NOT ANNUALISED) PER SHARE OF FACE VALUE OF Re. 1/- EACH</b>	<b>2.00</b>	<b>0.78</b>	<b>1.89</b>	<b>8.00</b>

**NOTES:-**

1. THE ABOVE UNAUDITED FINANCIAL RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD OF DIRECTORS AT ITS MEETING HELD ON JULY 27, 2016

2. THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2016 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR ENDED March 31, 2016 AND THE YEAR TO DATE THOSE FOR THE NINE MONTHS ENDED DECEMBER 31, 2015.

3. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.

**GEOGRAPHICAL SEGMENT DISCLOSURE:-**

- I) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 30, 2016 - RS. 1,291.75 LACS AND RS. 12,479.18 LACS RESPECTIVELY.
- II) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED MARCH 31, 2016- RS. 1,064.37 LACS AND RS. 12,976.70 LACS RESPECTIVELY.
- III) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 31, 2015- RS. 1,063.83 LACS AND RS. 8,283.90 LACS RESPECTIVELY.
- IV) REVENUES WITHIN AND OUTSIDE INDIA FOR THE YEAR ENDED MARCH 31, 2016- RS. 5,413.38 LACS AND RS. 48257.92 LACS RESPECTIVELY.

4. FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI  
 DATE : 27th July 2016

FOR BLISS GVS PHARMA LTD  
 SD/-  
 S.N. KAMATH  
 MANAGING DIRECTOR

**Limited Review Report**

The Board of Directors  
Bliss GVS Pharma Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Bliss GVS Pharma Limited for the quarter ended June 30, 2016 ("the Statement"). This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on standalone financial results for the quarter ended June 30, 2016 based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the applicable accounting standards specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to our reliance on management representation, in respect of the realisability of the Company's investment in and loan given to two of its subsidiaries (net of the amount realizable/receivable on disposal of a step down subsidiary) aggregating Rs. 8,827.12 lakhs.

Our conclusion is not modified in respect of this matter.

For B. K. Khare & Co.  
Chartered Accountants  
Firm Registration No. 105102W



Himanshu Chapsey  
Partner  
Membership No. 105731  
Mumbai, July 27, 2016

**Pune**

T + 91 020 60601005/6/7/8/9  
+ 91 020 25666932/32926341  
E bkkpune@bkkhareco.com  
Hotel Swaroop, 4th Floor,  
Lane No.10, Prabhat Road,  
Erandwane, Pune - 411 004, India

**Bengaluru**

T + 91 80 41105357  
E bkkbengaluru@bkkhareco.com  
101, Money Chambers,  
1st Floor, # 6 K. H. Road,  
Shanthinagar,  
Bengaluru - 560027, India

**New Delhi**

T + 91 011 4905 7624  
E bkkdelhi@bkkhareco.com  
A - 4, Westend,  
Rao Tula Ram Marg,  
New Delhi - 110021,  
India

### Limited Review Report

The Board of Directors  
Bliss GVS Pharma Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Bliss GVS Pharma Limited ("the Company") and its subsidiaries (the Company and its subsidiaries are collectively referred to as "the Group") for the quarter ended June 30, 2016 attached herewith ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on consolidated financial results for the quarter ended June 30, 2016, based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We did not perform a review on the financial statements of ten subsidiaries included in the quarterly consolidated financial results, whose interim financial statements reflect total assets (before consolidation adjustments) of Rs 39,277.56 lakhs as at June 30, 2016 as well as total revenue (before consolidation adjustments) of Rs 8,324.04 lakhs for the quarter ended June 30, 2016.
4. Of the entities referred to in para 3, the interim financial statements of and other financial information of
  - ▶ 7 subsidiaries whose interim financial statements reflect total assets (before consolidation adjustments) of Rs 28,597.13 lakhs as at June 30, 2016 as well as total revenue (before consolidation adjustments) of Rs 8,324.04 lakhs for the quarter ended June 30, 2016 have been reviewed by other auditors whose reports have been furnished to us and our opinion on the quarterly consolidated financial results, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors.

**Pune**

T + 91 020 60601005/6/7/8/9  
+ 91 020 25666932/32926341

E bkkpune@bkkhareco.com  
Hotel Swaroop, 4th Floor,  
Lane No.10, Prabhat Road,  
Erandwane, Pune - 411 004, India

**Bengaluru**

T + 91 80 41105357  
E bkkbengaluru@bkkhareco.com

101, Money Chambers,  
1st Floor, # 6 K. H. Road,  
Shanthinagar,  
Bengaluru - 560027, India

**New Delhi**


T + 91 011 4905 7624  
E bkkdelhi@bkkhareco.com

A - 4, Westend,  
Rao Tula Ram Marg,  
New Delhi - 110021,  
India

- ▶ 3 subsidiaries whose interim financial statements reflect total assets (before consolidation adjustments) of Rs 10,680.43 lakhs as at June 30, 2016 as well as total revenue (before consolidation adjustments) of Rs Nil for the quarter ended June 30, 2016 has not been subjected to a review. These interim financial statements have been furnished to us by management and our conclusion on the quarterly consolidated financial results, to the extent they have been derived from such interim financial statements of is based solely the interim financial statements provided to us by management. In our opinion, according to the information and explanations given to us by the management and in view of the fact that a substantial portion of the amounts referred to above eliminate on consolidation, these interim financial statements are not material to the consolidated financial results of the Group.
5. These quarterly consolidated financial results include the quarterly financial results of the following entities
- ▶ Bliss Indasi Lifesciences Private Ltd
  - ▶ Bliss GVS International Pte Ltd
  - ▶ Bliss GVS Clinic Healthcare Pte Ltd
  - ▶ Kremoint Pharma Private Ltd
  - ▶ Lifeon Labs Private Limited
  - ▶ Asterisk Lifesciences Limited
  - ▶ Shree Sales Pack Private Limited
  - ▶ Greenlife Bliss Healthcare Ltd
  - ▶ Bliss GVS Healthcare Ltd
  - ▶ Asterisk Lifesciences Ltd Ghana
  - ▶ Eipii Exports Pvt Ltd
6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of quarterly unaudited consolidated financial results prepared in accordance with the applicable accounting standards specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We draw attention to our reliance on the management representation that no provision is required for goodwill on consolidation arising in respect of its subsidiaries aggregating Rs 4,604.92 lakhs as at June 30, 2016.

Our opinion is not modified in respect of this matter.

For B. K. Khare & Co.  
Chartered Accountants  
Firm Registration No. 105102W

  
Himanshu Chapsey  
Partner  
Membership No. 105731



Mumbai, July 27, 2016